Skip to main content

Table 1 Patient characteristics

From: Circulating tumour necrosis factor-α bioactivity in rheumatoid arthritis patients treated with infliximab: link to clinical response

Characteristic

All RA patients (n = 42)

RA patients with a 1-year follow up (n = 20)

P

Age (years)

46.81 ± 10.78

48.05 ± 9.47

0.51

Sex (% female)

83 ± 11.27

70 ± 20.08

0.38

Disease duration (years)

8.98 ± 8.39

8.80 ± 8.01

0.82

Previous DMARD treatment (n)

2.78 ± 1.41

2.70 ± 2.70

0.47

Swollen joint count (0–28)

4.57 ± 3.16

4.55 ± 2.70

0.43

Tender joint count (0–28)

9.21 ± 5.78

8.35 ± 6.07

0.80

DAS28 score

5.33 ± 1.12

5.31 ± 1.19

0.76

ESR (mm/hour)

37.59 ± 23.18

37.45 ± 23.71

0.91

CRP (mg/l)

26.93 ± 24.87

31.30 ± 27.24

0.65

  1. Values are expressed as mean ± standard deviation. CRP, C-reactive protein; DAS28, Disease Activity Score 28; DMARD, disease-modifying antirheumatic drug; ESR, erythrocyte sedimentation rate; RA, rheumatoid arthritis.
Back to article page

Arthritis Research & Therapy

ISSN: 1478-6362

Contact us